M55 Stock Overview
A biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MacroGenics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.06 |
| 52 Week High | US$19.80 |
| 52 Week Low | US$2.63 |
| Beta | 2.08 |
| 11 Month Change | -4.32% |
| 3 Month Change | -2.80% |
| 1 Year Change | -55.00% |
| 33 Year Change | -81.75% |
| 5 Year Change | -63.79% |
| Change since IPO | -83.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| M55 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -9.3% | -0.2% | 0.8% |
| 1Y | -55.0% | -16.9% | 9.1% |
Return vs Industry: M55 underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: M55 underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| M55 volatility | |
|---|---|
| M55 Average Weekly Movement | 9.9% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: M55's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: M55's weekly volatility has decreased from 15% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 339 | Scott Koenig | www.macrogenics.com |
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company’s pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies.
MacroGenics, Inc. Fundamentals Summary
| M55 fundamental statistics | |
|---|---|
| Market cap | €193.76m |
| Earnings (TTM) | -€93.01m |
| Revenue (TTM) | €134.66m |
1.5x
P/S Ratio-2.1x
P/E RatioIs M55 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| M55 income statement (TTM) | |
|---|---|
| Revenue | US$141.33m |
| Cost of Revenue | US$192.63m |
| Gross Profit | -US$51.30m |
| Other Expenses | US$46.32m |
| Earnings | -US$97.62m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.56 |
| Gross Margin | -36.30% |
| Net Profit Margin | -69.07% |
| Debt/Equity Ratio | 0% |
How did M55 perform over the long term?
See historical performance and comparison